drugset / Trial / NCT00134875
Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers
RandomizedParallel-groupDouble-blindTreatment
Summary
Buprenorphine, a treatment for opioid dependence, can be mixed with another drug, naloxone, to limit abuse potential. Parenteral administration (intravenous or intramuscular injection) of buprenorphine/naloxone causes withdrawal symptoms in opioid dependent individuals. However, naloxone does not cause withdrawal symptoms in non-dependent opioid abusers. This study will investigate whether naloxone decreases the opioid agonist effect from injected buprenorphine, hence decreasing the abuse potential of buprenorphine/naloxone, in non-dependent opioid abusers.
Timeline
- Start
- 2000-12
- Primary completion
- 2002-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 4 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 8 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 16 mg | Other |
| Subject | Naloxone | Small molecule | 1 mg | Other |
| Subject | Naloxone | Small molecule | 2 mg | Other |
| Subject | Naloxone | Small molecule | 4 mg | Other |